KR20230104191A - 질환 치료를 위한 이환식 화합물 및 그 용도 - Google Patents

질환 치료를 위한 이환식 화합물 및 그 용도 Download PDF

Info

Publication number
KR20230104191A
KR20230104191A KR1020237018061A KR20237018061A KR20230104191A KR 20230104191 A KR20230104191 A KR 20230104191A KR 1020237018061 A KR1020237018061 A KR 1020237018061A KR 20237018061 A KR20237018061 A KR 20237018061A KR 20230104191 A KR20230104191 A KR 20230104191A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018061A
Other languages
English (en)
Korean (ko)
Inventor
린 카와스
케빈 처치
로버트 테일러
쥬얼 존스톤
더글라스 보트만
Original Assignee
아티라 파마, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아티라 파마, 인코포레이티드 filed Critical 아티라 파마, 인코포레이티드
Publication of KR20230104191A publication Critical patent/KR20230104191A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237018061A 2020-11-02 2021-11-01 질환 치료를 위한 이환식 화합물 및 그 용도 Pending KR20230104191A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
US63/108,660 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
KR20230104191A true KR20230104191A (ko) 2023-07-07

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018061A Pending KR20230104191A (ko) 2020-11-02 2021-11-01 질환 치료를 위한 이환식 화합물 및 그 용도

Country Status (13)

Country Link
US (1) US20240025903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236944A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884275B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230104191A (cg-RX-API-DMAC7.html)
CN (2) CN116568301A (cg-RX-API-DMAC7.html)
AR (1) AR124637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021371026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196582A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001195A1 (cg-RX-API-DMAC7.html)
IL (1) IL302465A (cg-RX-API-DMAC7.html)
MX (1) MX2023004942A (cg-RX-API-DMAC7.html)
TW (1) TWI918751B (cg-RX-API-DMAC7.html)
WO (1) WO2022094400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
KR20250005323A (ko) * 2022-05-04 2025-01-09 아티라 파마, 인코포레이티드 신경병증을 치료하는 방법
US20250275976A1 (en) * 2022-05-04 2025-09-04 Athira Pharma, Inc. Methods of Treating Neuroinflammatory Conditions
JP2025538382A (ja) 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
US8691819B2 (en) * 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
EP3366687B1 (en) * 2015-09-18 2020-04-29 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis

Also Published As

Publication number Publication date
EP4236944A1 (en) 2023-09-06
TWI918751B (zh) 2026-03-21
CL2024000340A1 (es) 2024-08-16
CN116568301A (zh) 2023-08-08
US20240025903A1 (en) 2024-01-25
CN119684295A (zh) 2025-03-25
CA3196582A1 (en) 2022-05-05
AU2021371026A1 (en) 2023-06-15
JP2023550543A (ja) 2023-12-01
AU2021371026A9 (en) 2024-04-18
JP7884275B2 (ja) 2026-07-03
AR124637A1 (es) 2023-04-19
IL302465A (en) 2023-06-01
CL2023001195A1 (es) 2023-10-20
TW202233622A (zh) 2022-09-01
MX2023004942A (es) 2023-07-06
EP4236944A4 (en) 2024-09-04
WO2022094400A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
AU2020413997B2 (en) Pyridazinyl-thiazolecarboxamide compound
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
WO2024077057A1 (en) Phenyl oxy amide kinase inhibitors
KR20240121239A (ko) 질환 치료를 위한 이환식 화합물의 용도
KR20250005230A (ko) 신경염증성 병태를 치료하는 방법
JP2025530793A (ja) Egfr阻害剤及びその使用
HK40122844A (en) Bicyclic compounds and uses thereof for the treatment of diseases
CN102741227B (zh) 芳基苄基胺化合物
HK40113746A (en) Uses of bicyclic compounds for the treatment of diseases
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
HK40097563A (en) Bicyclic compounds and uses thereof for the treatment of diseases
CN118382441A (zh) 双环化合物用于治疗疾病的用途
KR20250005323A (ko) 신경병증을 치료하는 방법
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
WO2025250930A1 (en) Hdac6 inhibitors and method of their use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000